Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biovaxys Technology Corp (CSE: BIOV )

0.0500 UNCHANGED
Streaming Delayed Price Updated: 3:59 PM EDT, Mar 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.0500
Bid (Size) 0.0450 (185,000)
Ask (Size) 0.0550 (70,000)
Prev. Close 0.0500
Today's Range 0.0500 - 0.0500
52wk Range 0.0400 - 0.0900
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
BioVaxys Technology Corp. to Present at the Life Sciences Investor Forum September 19th 2024
BioVaxys invites individual and institutional investors, as well as advisors and analysts, to attend online at www.VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire

Performance

YTD
-16.67%
-16.67%
1 Month
-9.09%
-9.09%
3 Month
-9.09%
-9.09%
6 Month
-16.67%
-16.67%
1 Year
-28.57%
-28.57%

More News

Read More
Life Sciences Virtual Investor Forum Agenda Announced for September 19th
From Virtual Investor Conferences
Via GlobeNewswire
The Power Play by The Market Herald Releases New Interviews with Reunion Gold Corp, Numinus Wellness, Core Assets, Blockmate Ventures, BioVaxys Tech, Carlyle Commodities and Belmont Resources Discussing Their Latest News
Via ACCESSWIRE
The Power Play by The Market Herald Releases New Interviews with Spey Resources, Melkior Resources and BioVaxys Technology Discussing Their Latest News
Via ACCESSWIRE
The Power Play by The Market Herald Releases New Interviews with ApartmentLove, Sirios Resources, Aton Resources, Mountain Boy Minerals and BioVaxys Technology Discussing Their Latest News
Via ACCESSWIRE
BioVaxys Announces Successful Test-Run Production of its Bi-Haptenized Ovarian Cancer Vaccine
Via FinancialNewsMedia
Research and Development of Advanced Therapeutics for Ovarian Cancer Fueling Hope
Via FinancialNewsMedia
Topics Intellectual Property
Exposures Intellectual Property
The Power Play by The Market Herald Releases New Interviews with RDARS, Infinity Stone Ventures, BioVaxys Technology, and Sitka Gold Discussing Their Latest News
Via ACCESSWIRE
Global Cervical Cancer Treatment Market Size Expected to Reach $11 Billion By 2027
Via FinancialNewsMedia
BioVaxys Executes Binding Term Sheet for the US Marketing & Distribution for Papilocare Gel and Oral Immunocaps
Via FinancialNewsMedia
The Power Play by The Market Herald Releases a New Interview with BioVaxys Technology Discussing Their Latest News
Via ACCESSWIRE
Advanced Clinical Trials Focus on Development of Vaccines to Prevent Ovarian Cancer Progression
Via FinancialNewsMedia
Topics Death
Exposures Death
BioVaxys Confirms First Clinical Site and Principal Investigators for Ovarian Cancer Vaccine Trial and Enters into Second Tumor Cell Supply Agreement
Via FinancialNewsMedia
Advanced Immunological and Clinical Trials for Treating Ovarian Cancer Accelerating
Via FinancialNewsMedia
Topics Intellectual Property
Exposures Intellectual Property
BioVaxys Enters Critical Tumor Cell Supply Agreement with Deaconess Research Institute for BVX-0918 Bioproduction
Via FinancialNewsMedia
Topics Economy
Exposures Supply Chain
The Power Play by The Market Herald Releases Interviews With Monarch Mining, Vox, Tocvan Ventures, GeneTether Therapeutics, Peloton Minerals, SWMBRD Sports, and BioVaxys Technology Corp.
From The Market Herald
Via AccessWire
Race to Develop Universal ‘Variant-Proof’ Covid Vaccine Involves Several Players
Via FinancialNewsMedia
Exposures COVID-19
Biotech Sector’s Response to Omicron Panic Should be Swift and Effective
Via FinancialNewsMedia
Exposures COVID-19
Anxious World Waits As Covid Vaccine Makers Address Omicron Variant
Via FinancialNewsMedia
Exposures COVID-19
Covid-19 Test Shortage Emphasized by New $70M Plan to Speed Up Authorizations
Via FinancialNewsMedia
Exposures COVID-19
Global COVID-19 Therapeutics Market Size Now Expected To Exceed $25 Billion In 2030
Via FinancialNewsMedia
Topics Death
Exposures COVID-19 Death
BioVaxys announces that CoviDTH Demonstrates Safety and Tolerability in Broad Ranging In Vivo Clinical Pathology, Immunology, and Histopathology Evaluation, Supporting Planned Clinical Development of CoviDTH
Via FinancialNewsMedia
Faster, Cheaper, More Reliable COVID-19 Tests Needed for the Unprecedented Demand Ahead
Via FinancialNewsMedia
Exposures COVID-19
Scientific Reports Revealing Early Promise for Universal Coronavirus Vaccine
Via FinancialNewsMedia
Exposures COVID-19
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.